TEVA PHARMACEUTICAL INDUSTRIES LTD

Key metrics

Financial performance

Over the last 9 fiscal years TEVA PHARMACEUTICAL INDUSTRIES LTD's revenue declined from $21.90B to $17.26B, a compound annual decline rate of 2.6%. Net profit margin expanded from 1.5% to 8.2% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (2,473 filings)

Recent press releases

• TEV-‘749 utilizes SteadyTeq™, a copolymer technology proprietary to Medincell that provides a controlled, steady, prolonged release of olanzapine.2026-05-21

  The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

• Fitch’s report highlights Teva’s sustained progress in strengthening financial flexibility and advancing its transition toward a higher-margin innovative and biosimilar portfolio. Fitch expects continued growth in innovative revenues, led by AUSTEDO® and AJOVY®; as well as contributions from recently launched products such as UZEDY® and upcoming launches, including olanzapine LAI, subject to regulatory approval. Fitch also expects Teva’s efficiency programs and portfolio shift to support its operating margin improvement and continued strong cash generation. Fitch further noted Teva’s ongoing balance sheet strengthening, supported by sustained cash flow generation, enhancing financial flexibility.2026-05-18

  Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

• “The latest data from the IMPACT-TD Registry underscores the profound, multidimensional impact of tardive dyskinesia on individuals, extending far beyond any single demographic. Despite its widespread impact, we are still confronted with meaningful diagnostic gaps, leaving many patients undiagnosed and untreated,” said Verena Ramirez Campos, MD-MBA, Vice President U.S. Medical Affairs and Global Innovative Strategy at Teva. “We are committed to grasping the complete human experience of TD, and working to help close those gaps and bring forth innovations that make a meaningful difference in the day-to-day lives of people living with TD.”2026-05-18

  Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

• This document and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our financial guidance, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements include statements concerning our plans, strategies, objectives, future performance and financial and operating targets, and any other information that is not historical information. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; our ability to develop and commercialize additional pharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; the effectiveness of our patents and other measures to protect our intellectual property rights; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this document, in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.2026-05-04
• Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets2026-04-30

  Teva exceeded all sustainability-linked bond targets, linking financial performance to expanded patient access to medicines and reduced environmental impact.

Similar companies

The largest companies sharing TEVA PHARMACEUTICAL INDUSTRIES LTD's SEC industry classification (pharmaceutical preparations).